Livingstone, R. , Boyle, J. G. and Petrie, J. R. (2017) A new perspective on metformin therapy in type 1 diabetes. Diabetologia, 60(9), pp. 1594-1600. (doi: 10.1007/s00125-017-4364-6) (PMID:28770327)
|
Text
143575.pdf - Published Version Available under License Creative Commons Attribution. 469kB |
Abstract
Metformin is quite frequently used off-label in type 1 diabetes to limit insulin dose requirement. Guidelines recommend that it can improve glucose control in those who are overweight and obese but evidence in support of this is limited. Recently-published findings from the REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL) trial suggest that metformin therapy in type 1 diabetes can reduce atherosclerosis progression, weight and LDL-cholesterol levels. This provides a new perspective on metformin therapy in type 1 diabetes and suggests a potential role for reducing the long-term risk of cardiovascular disease.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Boyle, Dr James and Petrie, Professor John and Livingstone, Dr Rachel |
| Authors: | Livingstone, R., Boyle, J. G., and Petrie, J. R. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
| Journal Name: | Diabetologia |
| Publisher: | Springer |
| ISSN: | 0012-186X |
| ISSN (Online): | 1432-0428 |
| Published Online: | 02 August 2017 |
| Copyright Holders: | Copyright © 2017 The Authors |
| First Published: | First published in Diabetologia 60(9):1594-1600 |
| Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information